ABT-737 is a subnanomolar inhibitor of the antiapoptotic proteins Bcl-2, Bcl-X L and Bcl-w. Although ABT-737 triggers extensive cell death in many small-cell lung carcinoma (SCLC) cell lines, some of the SCLC cell lines and the majority of the cancer cell lines derived from other solid tumors were found to be resistant to ABT-737. To better understand the mechanism of resistance to ABT-737, we screened a short interfering RNA library consisting of short interfering RNA against 4000 'druggable' targets in an SCLC-derived cell line, NCI-H196. By comparing the knockdowns with phenotypes, all of the three top 'hits' from the screen were found to result from off-target gene silencing. Interestingly, the three offtarget siRNAs were found to knock down an antiapoptotic Bcl-2 family protein Mcl-1 owing to the complementation between their seed regions with the 3 0 untranslated region (3 0 UTR) of Mcl-1. Furthermore, reducing the level of Mcl-1 using siRNAs or the small-molecule compounds Bay43-9006 and Seliciclib was sufficient to overcome the resistance to ABT-737 in the resistant SCLC cell line and cancer cell lines derived from other solid tumors. These results provide further evidence that Mcl-1 is the major factor that causes resistance to ABT-737 in cancer cells derived from diverse solid tumors, and the combination of Mcl-1 downregulating agents with ABT-737 could be potent therapeutic regimens for patient with ABT-737-resistant SCLC and many other types of solid tumors.
Introduction
RNA interference (RNAi) is a mechanism of posttranscriptional gene silencing using double-stranded RNA (Fire et al., 1998; Waterhouse et al., 2001; Tijsterman et al., 2002) . Since its discovery, RNAi quickly became the method of choice for studying the loss of function phenotypes in cells and animals. Although it was originally considered to be highly specific, it has been shown that siRNA can generate offtarget gene silencing (Jackson et al., 2003; Saxena et al., 2003; Zeng et al., 2003) , which could be detrimental to applications such as large-scale siRNA library screening (Lin et al., 2005) . Several recent studies suggest that the main source of siRNA-mediated off-target gene silencing could be the complementation between the 'seed' region of siRNAs (nucleotides 2-8 of the antisense strand) and the 3 0 untranslated region (3 0 UTR) of unintended targets (Jackson et al., 2003; Lin et al., 2005; Birmingham et al., 2006) . This opens up the possibility that authentic targets responsible for a desired phenotype may be identified by searching for genes with their 3 0 UTR complementing the 'seed' region of an off-target siRNA.
Proteins of the Bcl-2 family play a central role in regulating the apoptotic process (Danial and Korsmeyer, 2004) . Among the Bcl-2 family members, the anti-apoptotic proteins such as Bcl-2 and Bcl-X L are overexpressed in many cancers and likely contribute to tumor progression (Kirkin et al., 2004) , thus rendering these proteins compelling targets for cancer therapy. ABT-737 is a subnanomolar inhibitor of Bcl-2, Bcl-X L and Bcl-w (Oltersdorf et al., 2005) . It has been shown that ABT-737 induces potent cytotoxicity in cancer cell lines derived from small-cell lung carcinomas (SCLC) and B-cell lymphomas, and leads to regression of these tumors in preclinical models (Oltersdorf et al., 2005) . Although ABT-737 triggers extensive cell death in many SCLC cell lines, some of the SCLC lines and the majority of the cell lines derived from other solid tumors appear to be resistant to ABT-737 treatment (Oltersdorf et al., 2005) , suggesting that some of the SCLC patients and the majority of patients with other type of cancers may be resistant to ABT-737 as monotherapy. Previous microarray analysis of a panel of SCLC cells revealed that the mRNA levels of a large set of genes appeared to associate with cell sensitivity to unpublished data) . Among this set of sensitivityassociated genes are several Bcl-2 family members, such that relatively high levels of Bcl-2, Bim and Noxa appeared to associate with sensitivity and relatively high levels of Mcl-1 appeared to associate with resistance to ABT-737. However, it is not clear whether the differential expression of the Bcl-2 family members or many other genes reflects a non-causative association or a causative effect on cellular sensitivity to ABT-737. To better understand the mechanism of resistance to ABT-737, we screened a siRNA library consisting of 4000 'druggable' targets to identify genes that are responsible for the resistance of SCLC cells to ABT-737.
Results
RNAi-based library screen to identify genes responsible for ABT-737 resistance in NCI-H196 cells NCI-H196 is an SCLC-derived cell line that is resistant to ABT-737-induced cell death. Although ABT-737 triggers extensive apoptosis in many SCLC-derived cell lines at submicromolar concentrations, NCI-H196 cells can tolerate 20 mM of ABT-737 without undergoing profound cell death (data not shown). To identify cellular factors that confer resistance to ABT-737, we screened an siRNA library in NCI-H196 cells in the presence of an EC 20 (20 mM) of ABT-737 using a cell viability assay. From this initial screen, we identified 145 reproducible hits that induced a cell death phenotype above one standard deviation of the population mean. Re-assessment of these hits was performed in the presence or absence of compound to reveal that 29 of these hits induced hypersensitivity (more than 20% cell death) only in the presence of ABT-737. To select the best hits out of our initial 29, we further tested the Smartpool-transfected H196 cells for their responses to several different doses of ABT-737 or its less active enantiomer, A-793844 (Oltersdorf et al., 2005) . From these analyses, we identified 15 hits that induced at least a 20% decrease in cell survival in the presence of 1-10 mM ABT-737 compared to the less active enantiomer, suggesting that the siRNA-mediated sensitization is specific to the inhibition of Bcl-2 family proteins. Among the 15 hits, SmartPools against FGFR2, TNFRSF13B and PRDM13 were found to trigger the most dramatic decrease of cell survival in the presence of ABT-737 (more than 70% decrease of cell viability vs the 20-50% decrease induced by the rest of the 15 hits). Therefore, FGFR2, TNFRSF13B and PRDM13 were ranked as the top three hits. As a test for siRNA specificity, we next examined the correlations between siRNA-mediated knockdown and cell death phenotypes using four different siRNAs against different regions of the same gene for each hit. In these assessments, we found that the ability of these siRNAs to induce cell death in the presence of ABT-737 did not correlate with their ability to knock down the target genes. Specifically, among the FGFR2 siRNAs tested, only FGFR2-si2 caused a significant reduction in cell number in the presence of ABT-737 even though all four FGFR2 (a) NCI-H196 cells were transfected with 25 mM of a control siRNA (Con) or siRNAs against FGFR2 (FGFR2-si1 to si4), TNFRSF13B (TNFRSF13B-si1 to si4) and PRDM13 (PRDM13-si3 and si4) using Lipofectamine2000. Twenty-four hours after siRNA transfection, DMSO (DMSO) or ABT-737 (ABT-737) was added to the siRNA-transfected cells at a final concentration of 20 mM, and the ATPlite assay was performed 72 h post-siRNA transfection to determine percent cell viability. The number of surviving cells under each treatment was normalized to the number of surviving cells under the control treatment (transfected with the control siRNA and treated with DMSO), and the normalized number was designated as the 'Cell Viability (%)', which is represented by the Y-axis. (b) NCI-H196 cells were transfected with a control siRNA (Con) or siRNAs against FGFR2 (FGFR2-si1 to si4), TNFRSF13B (TNFRSF13B-si1 to si4) and PRDM13 (PRDM13-si3 and si4). Forty-eight hours after siRNA transfection, the cells were collected and the QuantiGene assay was performed to determine the mRNA levels of each target. The Y-axis represents artificial units of the mRNA level.
Role of Mcl-1 in resistance to the Bcl-2/Bcl-X L inhibitor ABT-737 X Lin et al siRNAs knocked down the target to a similar degree at the mRNA level (Figure 1a and b) . Similarly, among the siRNAs against TNFRSF13B and PRDM13, only TNFRSF13B-si3 and PRDM13-si4 induced a significant reduction in cell viability in the presence of ABT-737 even though several other siRNAs knocked down each target to a similar degree (Figure 1a and b) . The disconnection between siRNA-mediated target knockdown and sensitivity to ABT-737 suggests that the observed sensitization to ABT-737 by PRDM13-si4, TNFRSF13B-si3 and FGFR2-si2 is likely due to offtarget effects produced by these siRNAs. In a similar assessment, disconnections between cellular phenotype and target knockdown were also noticed using individual siRNAs against the rest of the 15 hits, indicating that all of them are off-target hits (data not shown).
The off-target siRNAs, FGFR2-si2, PRDM13-si4 and TNFRSF13B-si3, downregulate Mcl-1 owing to the complementation between their 'seed' regions and the 3 0 UTR of mcl-1 mRNA It has been suggested that the major source of siRNAmediated off-target gene silencing could be the complementation between the 'seed' region of siRNA (nucleotides 2-8 of the antisense strand) and the 3 0 UTR of unintended targets (Jackson et al., 2003; Lin et al., 2005; Birmingham et al., 2006) . Therefore, searching for genes with their 3 0 UTR complementing the 'seed' region of an off-target siRNA might allow for the identification of the authentic targets that are responsible for a desired phenotype. To identify the real target that is silenced by the off-target siRNAs and caused extensive cell death in the presence of ABT-737 in the NCI-H196 cells, we searched for genes that have their 3 0 UTR complementing the 'seed region' of the off-target siRNAs (FGFR2-si2, PRDM13-si4 and TNFRSF13B-si3). A close examination of the 'seed' regions of these siRNAs revealed that PRDM13-si4 and TNFRSF13B-si3 had the same seed sequence 'GGCAA GU', whereas FGFR2-si2 had a different seed sequence 'CCUAGUU'. A BLAST search of the human RefSeq database using the two seed sequences 'GGCAAGU' and CCUAGUU' resulted in two 'hit' lists containing 3312 and 2503 entries, respectively. Owing to the overwhelming number of hits from the BLAST search, we further looked for entries that appeared in both lists, assuming that the same target was knocked down by all the off-target siRNAs and caused sensitization to ABT-737. Three hundred and forty-three genes were found to have their 3 0 UTR matched with both the seed sequences. Among these 343 genes, Mcl-1, a Bcl-2 family protein, was of particular interest ( Figure 2a ). Because ABT-737 did not significantly inhibit Mcl-1, it is possible that high levels of Mcl-1 expression might compensate for the inhibition of Bcl-2 and Bcl-X L mediated by ABT-737. In parallel with the siRNA library screening, Mcl-1 was independently identified from expression profiling as one of the factors that influence SCLC cell sensitivity to ABT-737, and inhibition of Mcl-1 by siRNA was found to sensitize SCLC cells to unpublished data) . Taken together, these results suggest that the sensitization of NCI-H196 cells to ABT-737 triggered by the three off-target siRNAs could be due to their abilities to silence Mcl-1. To determine whether the three off-target siRNAs could downregulate Mcl-1, we examined the protein and mRNA levels of Mcl-1 in NCI-H196 cells transfected with FGFR2-si2, PRDM13-si4 and TNFRSF13B-si3. A clear reduction of Mcl-1 protein and mRNA level was observed in siRNA-transfected cells, indicating that the off-target siRNAs indeed knocked down Mcl-1 (Figure 2b and c) .
The observed downregulation of Mcl-1 by FGFR2-si2, PRDM13-si4 and TNFRSF13B could be due to the direct targeting of the mcl-1 mRNA by these siRNAs or could result from an indirect effect caused by knocking down an unknown protein that regulates Mcl-1. To distinguish between these possibilities, we created a . siRNAs that directly target the inserted mcl-1 3 0 UTR would be expected to trigger the degradation of the fusion mRNA produced from these constructs and lead to a reduction of luciferase activity. All the three off-target siRNAs were found to cause a reduction of luciferase activity when the fusion reporter contains the wild-type mcl-1 3 0 UTR (Figure 3b , Luc-Mcl1-wt). In contrast, no reduction of luciferase activity was observed when the reporter contained only the luciferase coding sequence (Figure 3b , Luc). These results suggest that FGFR2-si2, TNFRSF13B-si3 and PRDM13-si4 may directly target the 3 0 UTR of mcl-1 to trigger the silencing of Mcl-1.
To further test whether the two 7-nt motifs in the 3 0 UTR of mcl-1 (nucleotides 1511-1529 and nucleotides 1762-1780) are indeed the targeting sites of PRDM13-si4/TNFRSF13B-si3 and FGFR2-si2, respectively, we created fusion reporters with the two hypothetical targeting sites for these siRNAs disrupted individually (Figure 3a , Luc-Mcl-1-m1 and Luc-Mcl-1-m2). A mutation that disrupted the hypothetical FGFR2-si2 targeting site was found to completely block the ability of FGFR2-si2 to inhibit the reporter (Figure 3b) , suggesting that the nucleotides 1762-1780 of the mcl-1 3 0 UTR are responsible for FGFR2-si2-induced Mcl-1 knockdown. Interestingly, the mutation that disrupted the hypothetical targeting site for PRDM13-si4/ TNFRSF13B-si3 only partially blocked the ability of these siRNAs to inhibit the reporter (Figure 3b) , suggesting that there might be additional sites in the mcl-1 3 0 UTR that contribute to the off-target silencing of Mcl-1 by PRDM13-si4 or TNFRSF13B-si3.
Inhibition of Mcl-1 overcomes the resistance to ABT-737 in the NCI-H196 cells The observation that all three off-target siRNAs can trigger the knockdown of Mcl-1 suggests that Mcl-1 may be the authentic target that is responsible for the resistance to ABT-737 in the NCI-H196 cells, which is consistent with the earlier finding from gene expression analysis (Tahir et al., unpublished data) . To directly test this hypothesis, we obtained nine siRNAs against Mcl-1, and tested the ability of these siRNAs to induce cell death in the presence of ABT-737. A reduction of cell viability in the presence of ABT-737 was observed in cells transfected with the majority of the Mcl-1 siRNAs (Figure 4a ). In addition, the degree of cell death triggered by these siRNAs in the presence of ABT-737 appeared to correlate with the ability of each siRNA to knock down Mcl-1. For example, Mcl-1-si2, si3, si4 and si5, which induced a weak cell death phenotype upon ABT-737 treatment, correlated with a marginal knockdown of Mcl-1 (Figure 4b ). The close association between the degree of Mcl-1 knockdown and the severity of the phenotype indicates that the observed sensitization of NCI-H196 cells to ABT-737 upon siRNA transfection is unlikely due to off-target effects of the Mcl-1 siRNAs. In addition to downregulating Mcl-1 by siRNAs, it has been shown that the amount of Mcl-1 in cells can also be reduced by Bay43-9006 and Seliciclib in certain cell lines (Kitada et al., 2000; van de Donk et al., 2003; Yu et al., 2005) . When tested in the NCI-H196 cells, a significant reduction of Mcl-1 was observed in cells treated with Bay43-9006 or Seliciclib for 8 h (Figure 4c) . Accordingly, the combination of Bay43-9006 or Seliciclib with ABT-737 triggered robust cell death in the NCI-H196 cells, whereas the treatment of Bay43-9006, Seliciclib or ABT-737 alone did not significantly affect cell viability (Figure 4d ). These results collectively suggest that inhibition of Mcl-1 is sufficient to overcome the resistance to ABT-737 in the NCI-H196 cells, and therefore is likely the major factor responsible for ABT-737 resistance.
Downregulation of Mcl-1 sensitizes cancer cells derived from other solid tumors to ABT-737 treatment
The majority of the cell lines that are derived from solid tumors other than SCLC have been found to be resistant to ABT-737 (data not shown). As Western blot analysis of these resistant cell lines revealed that most of them express Mcl-1 (Figure 5a ), we tested whether Mcl-1 is also responsible for the resistance to ABT-737 observed Discussion siRNA-mediated large-scale gene knockdown experiments have been widely carried out for the identification of novel therapeutic targets or to gain new insight into complex biological processes. One of the difficulties in large-scale gene knockdown experiments is the possibility of siRNA-mediated off-target effects. Because the screening process enriches siRNAs that produce a particular phenotype, when thousands of siRNAs are used in a screen, the probability of obtaining off-target hits is quite high. As an example of how off-target gene silencing could be detrimental to siRNA library screening, all the three top 'hits' in our previous hypoxiainducible factor-1 (HIF-1) reporter screen were found to result from off-target gene silencing (Lin et al., 2005) . Similarly, all the top 'hits' in this study, siRNAs against FGFR2, PRDM13 and TNFRSF13B, were also found to result from off-target gene silencing. These results suggest that extreme caution should be used in interpreting siRNA screening results, and verifying the Role of Mcl-1 in resistance to the Bcl-2/Bcl-X L inhibitor ABT-737 X Lin et al screening 'hits' with multiple siRNAs against the same target is critical. Interestingly, all the off-target siRNAs obtained in this study were found to knock down an unintended target, Mcl-1, owing to the complementation between the siRNA 'seed' region and the mcl-1 3 0 UTR. This mode of off-target gene silencing was also observed in our previous HIF-1 reporter screen, in which all offtarget siRNAs had 'seed' regions complementary to the 3 0 UTR of an unintended target, HIF-1a (Lin et al., 2005) . Taken together, results from both studies reinforce the concept that the complementation between the 'seed' region of siRNA and the 3 0 UTR of unintended targets is the main source of off-target effects. Unexpectedly, the mutation that disrupted the hypothetical targeting site for PRDM13-si4/ TNFRSF13B-si3, GGCAAGU, only partially blocked the ability of these siRNAs to inhibit the reporter (Figure 3b ). Because both heptamer and hexamer matches between seed region and 3 0 UTRs have been reported to be associated with off-target gene silencing (Birmingham et al., 2006) , we performed further sequence analysis using the hexamer 'GCAAGU' to identify additional targeting sites for PRDM13-si4 and TNFRSF13B-si3. In addition to the previously identified hypothetical targeting site, 'GGCAAGU', three Role of Mcl-1 in resistance to the Bcl-2/Bcl-X L inhibitor ABT-737 X Lin et al 'GCAAGU' motifs were identified in the 3 0 UTR of Mcl-1. We suspect that the three 'GCAAGU' motifs might serve as additional targeting sites for PRDM13-si4 and TNFRSF13B, which explains the incomplete reversal of off-target gene silencing by mutating the GGCAAGU site.
When the siRNA study was in progress, Mcl-1 was identified from expression profiling studies as one of the factors that influence the cellular response of SCLC cells to ABT-737, and siRNAs against Mcl-1 were shown to sensitize SCLC cells to unpublished data) . Intriguingly, although Mcl-1 siRNAs were present in the siRNA library used for the screen, Mcl-1 was not identified as a hit from the screening. Retrospective testing of all four Mcl-1 siRNAs in the library revealed that none of these siRNAs were able to sensitize H196 cells to ABT-737, suggesting that these siRNAs may not be functional. However, by searching for genes that have their 3 0 UTR matching the 'seed' region of off-target siRNAs, we are able to uncover Mcl-1 as the authentic target that was silenced by the off-target siRNAs and led to the reversion of resistance to ABT-737 in the NCI-H196 cells. These results demonstrate that off-target siRNAs are a useful source of information, and authentic targets that are responsible for the phenotype can be identified through 'seed analysis' of off-target siRNA.
It has been shown that ABT-737, a subnanomolar Bcl-2 family inhibitor, could be a very promising therapeutic agent for treating SCLC and B-cell lymphoma. However, for cancer cells derived from other solid tumors, ABT-737 has very limited activity as a single agent. The identification of Mcl-1 as a resistance factor to ABT-737 in cell lines derived from SCLC and many other solid tumors suggests that Mcl-1-mediated resistance to ABT-737 could be a common phenomenon in patients with diverse cancer types. These findings could have important ramifications regarding how to use ABT-737 in the clinical setting. For example, for patients who have high levels of Mcl-1 expression, a rational therapeutic strategy could be the combination of ABT-737 with an agent that inhibits Mcl-1 function. The ability of Bay43-9006 and Seliciclib to downregulate Mcl-1 and sensitize the resistant SCLC cell line NCI-H196 to ABT-737 treatment suggests that the combination of these compounds with ABT-737 could serve as a useful therapeutic approach for the treatment of ABT-737-resistant SCLC patients and patients with diverse types of solid tumors.
Materials and methods
Cell culture, transfection and the cytotoxicity assay The NCI-H196 cells were maintained in RPMI-1640 media supplemented with 10% human serum (Sigma, St Louis, MO, USA). The EJ-1 cells were cultured in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS). The D54MG cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS. The HCT-116 and DLD-1 were cultured in the RPMI-1640 medium supplemented with 10% FBS. Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) was used to introduce siRNAs into cells according to the manufacturer's suggested protocol. For all siRNA experiments, the siRNAs were transfected at a final concentration of 20 nM. The ATPlite assay (PerkinElmer Life Sciences, Downers Grove, IL, USA) was used for a quantitative evaluation of proliferation and/or cytotoxicity of cultured cells.
siRNA library screen to identify genes that cause resistance to ABT-737 in NCI-H196 cells The 4000 'druggable' targets were selected based on Abbott's internal bioinformatics analysis. These include 519 protein kinases, 374 GPCRs, 399 peptidases, 233 ion channels, 48 nuclear receptors, 417 E3 ligase, 199 dehydrogenases, 353 transporters, 456 potential membrane targets, 76 phosphatases, 23 integrins, 101 chemokines, 195 lipid-modifying enzymes and more than 600 other cancer-related genes that do not fall into these categories. siRNAs against each gene were designed, synthesized and purified at Dharmacon Research, Inc. (Lafayette, CO, USA), whereby each mRNA is targeted by a mixture of four siRNA duplexes (SMARTpool). To identify genes responsible for the resistance to ABT-737, the NCI-H196 cells were transfected with the siRNA library at a final concentration of 25 nM/target. In brief, for a single well of a 96-well plate, 6 ml of siRNA and 2 ml of Lipofectamine2000 (Invitrogen Corp., Carlsbad, CA, USA) were each incubated separately with 100 ml of Opti-MEM for 10 min, mixed together for 20 min at room temperature and then 20 ml of mixture was applied to the cells plated in 100 ml of medium. The cells were incubated in the siRNA-transfection reagent mixture for 5-6 h before receiving fresh medium (100 ml). Gene expression analysis using quantitative reverse transcriptase-polymerase chain reaction and branched DNA assays mRNA expression levels were examined using the QuantiGene Assay (Genospectra, Inc., Fremont, CA, USA) according to the manufacturer's instructions. Expression levels of each sample were normalized to cyclophilin B. For quantitative reverse transcriptase-polymer chain reaction analysis, total RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA, USA) and gene expression was analysed using the ABI-7700 Sequence Detector instrument and the Platinum Quantitative RT-PCR ThermoScript One-Step System (Invitrogen, Carlsbad, CA, USA). The expression level of each sample was first normalized to the amount of glyceraldehyde-3-phosphate dehydrogenase or b-actin and then to the experimental control as previously described (Lin et al., 2005) .
Reporter assay for testing the response of Luc-mcl-1 fusion reporters to siRNAs The firefly luciferase gene (luc) and DNA fragments containing the wild-type or mutant mcl-1 3 0 UTRs were cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA). H1299 cells grown in a 96-well plate were first transfected with 20 nM siRNA for 24 h and then transfected with various Luc-mcl-1 fusion reporters together with a control reporter, pRL-SV40 (Promega, Madison, WI, USA). The cells were analysed 24 h after reporter transfection using the Dual-Glo luciferase assay system (Promega, Madison, WI, USA).
